Prostate Cancer P D:良性前列腺增生中,双极等离子前列腺剜除术与开放前列腺切除术比较

2018-09-03 AlexYang MedSci原创

最近,有研究人员在一个单中心群体研究的前列腺肥大(>80g)患者中比较了双极等离子前列腺剜除术与开放前列腺切除术的手术治疗结果和安全性。所有由于良性前列腺增生而患有下尿路症状的患者在2012年5月和2013年12月之间均经历双极等离子前列腺剜除术(TUEP)或者开放前列腺切除术(OP)。研究人员在术后的0, 1, 3, 6, 12, 24和36个月时对临床历史、身体检查、尿路症状、阴茎勃起功

最近,有研究人员在一个单中心群体研究的前列腺肥大(>80g)患者中比较了双极等离子前列腺剜除术与开放前列腺切除术的手术治疗结果和安全性。

所有由于良性前列腺增生而患有下尿路症状的患者在2012年5月和2013年12月之间均经历双极等离子前列腺剜除术(TUEP)或者开放前列腺切除术(OP)。研究人员在术后的0, 1, 3, 6, 12, 24和36个月时对临床历史、身体检查、尿路症状、阴茎勃起功能、尿流量和前列腺体积数据进行了收集,并且还记录了早期和长期的并发症。研究发现,总共包括了240名患者。其中111名患者(46%)经历了OP,129名患者(54%)经历了B-TUEP。考虑到疗效,2中手术都表现出了持久的结果,在第3年时OP组的再次介入率为7.5%,B-TUEP组为5%。考虑到安全性,与OP组相比,B-TUEP表现出了更少的高等级并发症。

最后,研究人员指出,在他们的单中心研究中,B-TUEP代表了一种相对OP来说可靠的选择,且在第3年的治疗结果更为优秀。进一步的多中心是需要的,从而进一步确认他们的结果。

原始出处:

Roberto Giulianelli, Barbara Cristina Gentile, Gabriella Mirabile et al. Bipolar plasma enucleation of the prostate vs. open prostatectomy in large benign prostatic hyperplasia: a single centre 3-year comparison. Prostate Cancer P D. 21 Aug 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1708838, encodeId=cfcc1e088380b, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Wed May 01 06:17:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791544, encodeId=8a941e915449a, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Mar 17 01:17:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877055, encodeId=7c5518e705578, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Jul 15 08:17:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364380, encodeId=e76d13643808a, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509689, encodeId=c78a150968939, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602047, encodeId=a406160204e56, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1708838, encodeId=cfcc1e088380b, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Wed May 01 06:17:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791544, encodeId=8a941e915449a, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Mar 17 01:17:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877055, encodeId=7c5518e705578, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Jul 15 08:17:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364380, encodeId=e76d13643808a, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509689, encodeId=c78a150968939, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602047, encodeId=a406160204e56, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1708838, encodeId=cfcc1e088380b, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Wed May 01 06:17:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791544, encodeId=8a941e915449a, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Mar 17 01:17:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877055, encodeId=7c5518e705578, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Jul 15 08:17:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364380, encodeId=e76d13643808a, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509689, encodeId=c78a150968939, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602047, encodeId=a406160204e56, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1708838, encodeId=cfcc1e088380b, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Wed May 01 06:17:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791544, encodeId=8a941e915449a, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Mar 17 01:17:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877055, encodeId=7c5518e705578, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Jul 15 08:17:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364380, encodeId=e76d13643808a, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509689, encodeId=c78a150968939, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602047, encodeId=a406160204e56, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=)]
    2018-09-05 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1708838, encodeId=cfcc1e088380b, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Wed May 01 06:17:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791544, encodeId=8a941e915449a, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Mar 17 01:17:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877055, encodeId=7c5518e705578, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Jul 15 08:17:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364380, encodeId=e76d13643808a, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509689, encodeId=c78a150968939, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602047, encodeId=a406160204e56, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1708838, encodeId=cfcc1e088380b, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Wed May 01 06:17:00 CST 2019, time=2019-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791544, encodeId=8a941e915449a, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Sun Mar 17 01:17:00 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877055, encodeId=7c5518e705578, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Mon Jul 15 08:17:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364380, encodeId=e76d13643808a, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509689, encodeId=c78a150968939, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602047, encodeId=a406160204e56, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Wed Sep 05 01:17:00 CST 2018, time=2018-09-05, status=1, ipAttribution=)]
    2018-09-05 sunylz

相关资讯

Lancet Oncol:机器人辅助手术为前列腺癌症患者带来更多选择

澳大利亚研究人员日前在英国医学期刊《柳叶刀·肿瘤学》上发表报告称,机器人辅助的前列腺癌根治手术为患者提供了安全的微创手术选择,其术后效果与开放性手术是一样的。

Nat Genet:大数据!对14万男性的相关分析鉴定了63个新的前列腺癌易感位点

到目前为止,全基因组关联分析(GWAS)和精心定位工作已经鉴定了不少于100个前列腺癌(PrCa)易感位点。最近,有研究人员对欧洲人口中的46939个高密度PrCa案例和27910个对照的基因型数据进行了元分析,并对之前报道过的欧洲血统的32255个PrCa案例和33202个对照的基因型数据也同时进行了元分析。研究发现,他们鉴定了62个新的与PrCa相关的位点(P<5.0×10-8),并且其

Prostate Cancer P D:经历最小侵入性根治前列腺切除术的男性中,淋巴结清除和30天围手术期发病率相关性分析

经历根治性前列腺癌切除术男性淋巴结清除(LND)发病率的增加仍旧不清楚。最近,有研究人员评估了经历最小侵入性根治前列腺切除术(MIRP)的男性中,LND与围手术期发病率之间侧相关性。研究包括了经历MIRP的年龄在35-89岁的29012名男性,时间为2010年到2015年。研究发现,手术的平均年龄为63(IQR 57, 67)岁。LND表现中的一些基线特征分层是具有统计学显著差异的,但是在临床上并

Urology:日常泌尿外科服务中前列腺体积评估新方法

最近,有研究人员开发了一个简单的前列腺体积(PV)计算方法,该方法能够帮助亚洲国家日常泌尿外科服务中患有前列腺肥大患者的下尿路症状的治疗。研究人员进行了一项代表性的研究,参与者年龄大于40岁,且没有前列腺癌、前列腺外科手术或者5α-还原酶抑制剂治疗历史。研究人员测量了每一为参与者的血清前列腺特异性抗原(PSA)和总PV,并且搜集了社会人口统计数据和临床变量,包括了年龄、体重、并发症和国际前列腺症状

Int J Impot Res:在美国男性大前列腺群体中,由于BPH引起LUTS 的Aquablation手术治疗结果研究

2017年9月到12月之间,在美国的一个前瞻性多中心临床试验中,82名由于良性前列腺增生LUTS/BPH和前列腺体积体积80-150cc而引起中度到重度下尿路症状的男性患者进行了Aquablation手术治疗。研究人员收集了基线患者、临床人口统计资料和标准化的术后参数,并在一个中心独立检测数据库制表整理。为期3个月的副作用事件通过一个独立的临床事件委员会进行裁决。研究发现,治疗前前列腺体积的平均值

Cancer Med:血清中类胰岛素生长因子-1、生物有效性睾酮水平和病理性格林森得分相关性研究

最近,有研究人员评估了血清中类胰岛素生长因子-1(IGF-1)、生物有效性睾酮水平和病理性格林森得分(GS)之间的相关性。研究包括了793名经历了根治性前列腺切除术的患者和272名阴性前列腺活检的男性患者。研究人员在手术或者生物活检前测量了血清中的IGF-1和睾丸素水平。研究发现,前列腺癌患者和阴性活检男性的IGF-1平均水平分别为143.8和118.9ng/mL(P<0.001)。具有高血